A Phase 3 interventional study of Rosuvastatin and Placebo in Atherosclerosis, sponsored by AstraZeneca. Completed at 24 sites in China. Open to participants aged 45 Years to 69 Years. Per ClinicalTrials.gov, last updated 2019-12-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing rosuvastatin in Atherosclerosis — 1 open to participants now, 2 under way, 1 of them phase 3. rosuvastatin · Atherosclerosis.
Among the 25 studies testing rosuvastatin in Atherosclerosis, this one is the 3rd largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2015, is one of 6 in phase 3, and was the 18th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 225 are open to participants now.
Browse Atherosclerosis studies →1 of the 25 studies testing rosuvastatin in Atherosclerosis is open now, in 1 country. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 30–60
By country, each count listing its studies:
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 161 Atherosclerosis studies recruiting now, 84 (52%) set no upper age limit and 33 (20%) stop at 75 or younger; 16 take children under 18; 33 take healthy volunteers.
This study: 45 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 543 is above the median of 100 across 880 interventional studies indexed under Atherosclerosis.
Median enrollment 77 across the 24 interventional studies. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 25 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
21 studies in Atherosclerosis by AstraZeneca: 1 open now, 2 under way, 2 of them phase 3. Of 19 finished, 4 (21%) have results posted.
Among the 21 studies in Atherosclerosis by AstraZeneca, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2015, is one of 5 in phase 3, and was the 12th registered.
AstraZeneca’s Atherosclerosis studies by the year they started, since 2004.
1 of the studies testing rosuvastatin in Atherosclerosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05850091Massachusetts General HospitalPolygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing rosuvastatin in Atherosclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 21 in Atherosclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of of rosuvastatin 20 mg compared to placebo for treating Chinese patients with subclinical atherosclerosis.
This study is a randomized, double-blind, placebo-controlled, multicenter parallel group study assessing the effects of rosuvastatin 20 mg treatment for 104 weeks on the change in intimamedia thickness (IMT) of the common carotid artery (CCA), carotid bulb, and internal carotid artery (ICA) in adult Chinese subjects with subclinical atherosclerosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 mg tablets, Daily oral dose
Drug: Rosuvastatin
Matching placebo tablets
Drug: Placebo
20mg tablets, orally once daily for the duration of the 104-week treatment period
Also known as: Crestor
Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period
CIMT measurements were made from ultrasound images of the common carotid artery (CCA), carotid bulb and internal carotid artery (ICA). The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. Twelve carotid artery sites were scanned at each visit and the 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for a specific segment. The annualized rate of change in the MeanMax CIMT measurements from each of the 12 sites, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.
Time frame: From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).
Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left CCA
CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.
Time frame: From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).
Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left Carotid Bulb
CIMT measurements were made from ultrasound images of the near and far walls of the right and left carotid bulb. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.
Time frame: From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).
Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left ICA
CIMT measurements were made from ultrasound images of the near and far walls of the right and left ICA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.
Time frame: From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).
Annualized Rate of Change in the Mean of the Mean (MeanMean) CIMT of the Near and Far Walls of the Right and Left CCA
CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the mean of the CIMT for this segment. The annualized rate of change in the MeanMean CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.
Time frame: From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).
Percent Change From Baseline in Lipid, Lipoprotein and Apolipoprotein Values at Final Visit: Last Observation Carried Forward (LOCF)
The percent change from baseline at final visit for lipid and lipoprotein measurements (low-density lipoprotein cholesterol \[LDL-C\], total cholesterol, high-density lipoprotein cholesterol \[HDL-C\], triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) and apolipoprotein measurements (apolipoprotein A-I \[ApoA-I\], apolipoprotein B \[ApoB\] and ApoB/ApoA-I ratio) was determined by analysis of covariance (ANCOVA) with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0) to the final visit at Week 104, any missing observations were imputed by LOCF.
Time frame: From baseline (Week 0) to end-of-study (Week 104).
Percent Change From Baseline in Lipid and Lipoprotein Values at Final Visit: Time Weighted Average
The percent change from baseline at final visit for lipid and lipoprotein measurements (LDL-C, total cholesterol, HDL-C, triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) was determined by ANCOVA with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0), the time-weighted average value was calculated as the value multiplied by the number of days since the last assessment, summed for all observations, and divided by the sum of days between all visits.
Time frame: From baseline (Week 0) to end-of-study (Week 104).
Chinese patients with subclinical atherosclerosis and a 10-year ischemic cardiovascular disease (ICVD) risk of less than 10% (as assessed by the 2007 China Adult Dyslipidema Management Guidelines) were enrolled at 25 sites in China between 17 September 2015 and 29 January 2019.
| Milestone | Rosuvastatin 20 mg | Placebo |
|---|---|---|
| Started | 272 | 271 |
| Received treatment | 272 | 268 |
| Completed | 212 | 205 |
| Not completed | 60 | 66 |
| Withdrew: Withdrawal by subject | 36 | 33 |
| Withdrew: Eligibility criteria not fulfilled | 0 | 1 |
| Withdrew: Adverse event | 17 | 11 |
| Withdrew: Patient specific reasons | 1 | 2 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Non-compliance with study drug | 2 | 2 |
| Withdrew: Met withdrawal criteria | 2 | 14 |
CIMT measurements were made from ultrasound images of the common carotid artery (CCA), carotid bulb and internal carotid artery (ICA). The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. Twelve carotid artery sites were scanned at each visit and the 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for a specific segment. The annualized rate of change in the MeanMax CIMT measurements from each of the 12 sites, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.
| mm/year | Rosuvastatin 20 mg | Placebo |
|---|---|---|
| Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period | 0.0038 ± 0.00312 | 0.0142 ± 0.00317 |
CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.
| mm/year | Rosuvastatin 20 mg | Placebo |
|---|---|---|
| Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left CCA | -0.0031 ± 0.00310 | 0.0079 ± 0.00315 |
CIMT measurements were made from ultrasound images of the near and far walls of the right and left carotid bulb. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.
| mm/year | Rosuvastatin 20 mg | Placebo |
|---|---|---|
| Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left Carotid Bulb | 0.0067 ± 0.00634 | 0.0228 ± 0.00643 |
CIMT measurements were made from ultrasound images of the near and far walls of the right and left ICA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.
| mm/year | Rosuvastatin 20 mg | Placebo |
|---|---|---|
| Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left ICA | 0.0077 ± 0.00502 | 0.0120 ± 0.00511 |
CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the mean of the CIMT for this segment. The annualized rate of change in the MeanMean CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.
| mm/year | Rosuvastatin 20 mg | Placebo |
|---|---|---|
| Annualized Rate of Change in the Mean of the Mean (MeanMean) CIMT of the Near and Far Walls of the Right and Left CCA | -0.0011 ± 0.00191 | 0.0075 ± 0.00194 |
The percent change from baseline at final visit for lipid and lipoprotein measurements (low-density lipoprotein cholesterol \[LDL-C\], total cholesterol, high-density lipoprotein cholesterol \[HDL-C\], triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) and apolipoprotein measurements (apolipoprotein A-I \[ApoA-I\], apolipoprotein B \[ApoB\] and ApoB/ApoA-I ratio) was determined by analysis of covariance (ANCOVA) with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0) to the final visit at Week 104, any missing observations were imputed by LOCF.
| Percent change | Rosuvastatin 20 mg | Placebo |
|---|---|---|
| LDL-C | -26.47 ± 1.700 | 8.99 ± 1.727 |
| Total Cholesterol | -20.56 ± 1.010 | 1.29 ± 1.026 |
| HDL-C | 5.47 ± 0.944 | 0.48 ± 0.959 |
| Triglycerides | -7.26 ± 2.575 | 12.38 ± 2.616 |
| Non-HDL-C | -27.67 ± 1.344 | 1.82 ± 1.365 |
| Non-HDL-C/HDL-C | -28.52 ± 1.637 | 3.23 ± 1.663 |
| ApoB | -24.20 ± 1.307 | 1.91 ± 1.295 |
| ApoA-I | 3.16 ± 0.784 | 0.96 ± 0.777 |
| ApoB/ApoA-I | -25.14 ± 1.450 | 1.63 ± 1.436 |
The percent change from baseline at final visit for lipid and lipoprotein measurements (LDL-C, total cholesterol, HDL-C, triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) was determined by ANCOVA with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0), the time-weighted average value was calculated as the value multiplied by the number of days since the last assessment, summed for all observations, and divided by the sum of days between all visits.
| Percent change | Rosuvastatin 20 mg | Placebo |
|---|---|---|
| LDL-C | -34.89 ± 1.275 | 4.62 ± 1.295 |
| Total Cholesterol | -23.98 ± 0.798 | 1.49 ± 0.811 |
| HDL-C | 7.07 ± 0.737 | 3.41 ± 0.748 |
| Triglycerides | -9.05 ± 2.091 | 9.36 ± 2.124 |
| Non-HDL-C | -32.59 ± 1.072 | 1.19 ± 1.089 |
| Non-HDL-C/HDL-C | -34.31 ± 1.288 | -0.38 ± 1.308 |
Collected over Treatment Emergent Adverse Events were collected from day of first dose in Week 0 up to and including 10 days following the date of last dose of investigational product or placebo (up to Week 104).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin 20 mg | 0/272 (0%) | 38/272 (14%) | 144/272 (52.9%) |
| Placebo | 1/268 (0.4%) | 34/268 (12.7%) | 142/268 (53%) |
| Event | Rosuvastatin 20 mg | Placebo |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/272 | 2/268 |
| Arteriosclerosis coronary arteryCardiac disorders | 1/272 | 2/268 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/272 | 2/268 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/272 | 2/268 |
| CataractEye disorders | 2/272 | 1/268 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 2/272 | 0/268 |
| Cerebral infarctionNervous system disorders | 2/272 | 0/268 |
| Angina unstableCardiac disorders | 0/272 | 1/268 |
| ArrhythmiaCardiac disorders | 1/272 | 1/268 |
| Coronary artery diseaseCardiac disorders | 0/272 | 1/268 |
| Event | Rosuvastatin 20 mg | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 52/272 | 56/268 |
| Upper respiratory tract infectionInfections and infestations | 49/272 | 54/268 |
| Blood glucose increasedInvestigations | 24/272 | 18/268 |
| ToothacheGastrointestinal disorders | 23/272 | 15/268 |
| HypertensionVascular disorders | 19/272 | 21/268 |
| DizzinessNervous system disorders | 14/272 | 16/268 |
| Protein urine presentInvestigations | 16/272 | 9/268 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/272 | 15/268 |
The intent-to-treat (ITT) analysis set consisted of all randomized patients.
| Age, Continuous(years) | Rosuvastatin 20 mg | Placebo | Total |
|---|---|---|---|
| Mean | 59.0 ± 5.23 | 59.7 ± 4.96 | 59.4 ± 5.11 |
| Sex: Female, Male(Participants) | Rosuvastatin 20 mg | Placebo | Total |
|---|---|---|---|
| Female | 146 | 158 | 304 |
| Male | 126 | 113 | 239 |
| Race/Ethnicity, Customized(Participants) | Rosuvastatin 20 mg | Placebo | Total |
|---|---|---|---|
| Asian | 272 | 271 | 543 |
| 10-year ICVD Risk(Participants) | Rosuvastatin 20 mg | Placebo | Total |
|---|---|---|---|
| <5% | 196 | 195 | 391 |
| ≥5% - <10% | 76 | 76 | 152 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2015 to primary completion in Jan 2019, 40 months.
Results were first posted in Dec 2019, 10 months after primary completion.
Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 40 months is above that.
Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin